期刊文献+

贝尼地平和缬沙坦联合治疗对高血压病患者肾功能的影响 被引量:10

Influence of Benidipine and Valsartan combination therapy on renal function of patients with hypertension
下载PDF
导出
摘要 目的探讨贝尼地平、缬沙坦单独治疗和联合治疗对高血压病患者肾脏的影响。方法将140例高血压病患者分为三组:A组(口服贝尼地平4 mg)、B组(口服缬沙坦80 mg)、C组(口服贝尼地平4 mg和缬沙坦80 mg)。疗程24周,观察治疗前后血压和肾功能的变化。结果 C组降低血压和降低尿蛋白排泄的幅度优于A、B组(P<0.01),治疗后肾小球滤过率在C组及A、B组之间,差异有高度统计学意义(P<0.01)。结论贝尼地平、缬沙坦长期单独治疗均可减少蛋白尿,保护肾脏,两药联合治疗对减少蛋白尿、保护肾脏有一定协同作用。 Objective To investigate the influence of Benidipine and Valsartan monotherapy and combination therapy on the renal function of patients with hypertension.Methods 140 patients with hypertension were randomly divided into three groups: group A(oral administration of 4 mg of Benidipine),group B(oral administration of 80 mg of Valsartan) and group C(oral administration of 4 mg of Benidipine and 80 mg of Valsartan).After 24 weeks of treatment,the changes of blood pressure and renal function before and after treatment were observed.Results The group C was superior to group A and B in the reduction of blood pressure and urinary protein excretion(P 0.01).After treatment,the glomerular filtration rate was different among group C with group A and B,with statistical significance(P 0.01).Conclusion Long-term Benidipine and Valsartan monotherapies can both reduce proteinuria and protect the kidneys.The combination therapy has certain synergistic effect on the reduction of proteinuria and protection of kidneys.
出处 《中国医药导报》 CAS 2012年第14期95-96,99,共3页 China Medical Herald
关键词 高血压病 贝尼地平 缬沙坦 肾功能 Hypertension Benidipine Valsartan Renal function
  • 相关文献

参考文献14

  • 1Tamsma JT,Jazet IM,Beishuizen ED,et al. The metabolic sydrome:a vascular perspective [J]. Eur J Intern Med, 2005,16 (5) : 314-320.
  • 2李为民,刘巍.2005年中国高血压防治指南评介[J].中国实用内科杂志,2007,27(12):899-902. 被引量:73
  • 3Qin XP,Ye F,Liao DF,et al. Involvement of calciton in generelated peptide in depressor effects of losartan and perindopril in rats [J]. Eur J Pharmaeol, 2003,464 ( 1 ) : 63-67.
  • 4Uzu T,Nishimura M,Fujii T,et al. Benidipine attenuates glomerruler hypertension and reduces albuminuria in patients with metabolic syn- drome [J]. Hypertens Res, 2007,30 : 161-165.
  • 5Akizuki O,lnayoshi A,Kitayama T,et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine A dihydropyridine calcium chan- nel blocker,inhibits aldosterone production in human adrenocortical cell line NCI-H295 R [J]. Eur J Pharmacol, 2008,584 : 424-434.
  • 6Saito F,Fujita H,Takahashi A,et al. Renoprotective effect and cost-ef- fectiveness of using benidipine,a calcium channel blocker,to lower the dose of angiotensin receptor blocker in hypertensive patients with albu- minuria [J]. Hylxntens Res, 2007,30 : 39-47.
  • 7Hayashi K,Wakino S,Homma K,et al. Pathophysiological significance of T-type Ca2+ channel:role of T-type Ca2+ channel in renal microcircu- lation [J]..l Pharmacol Sci ,2005,99:221-227.
  • 8Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease [J]. Curr Opin Nephrol Hypertens,2004,13:155-161.
  • 9Matsuzaki G,Ishizaka N ,Furuta K,et al. Comparison of vasculoprotec-tive effects of benidipine and losartan in a rat model of metabolic syn- drome [J]. Eur J Pharmaeol,2008,587:237-242,.
  • 10Croom KF,Curran MP,Goa KL,et al. Irbesartan:a review of its use in hypertension and in the management of diabetic nephropathy [J]. Drugs, 2004,64 : 999-1028.

二级参考文献34

共引文献122

同被引文献68

  • 1侯凡凡,谢迪.慢性肾脏病应用肾素-血管紧张素系统阻断剂的治疗目标[J].中华高血压杂志,2007,15(z1):32-34. 被引量:13
  • 2刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1216
  • 3张维忠.新型钙拮抗剂贝尼地平基础与临床研究进展[J].高血压杂志,2005,13(4):196-197. 被引量:33
  • 4杨漫沩.苯磺酸左旋氨氯地平治疗高血压的疗效及不良反应观察[J].实用心脑肺血管病杂志,2007,15(2):135-135. 被引量:9
  • 5Peleg E,Mosheiff R,Liebergall M,et al.A short plate compression screw with diagonal bolts-a biomechanical evaluation performed experimentally and by numerical computation[J].Clinical Biomechanics (Bristol,Avon),2006,21(9):963-968.
  • 6刘国树.钙离子通道阻滞剂治疗高血压病新进展[J].中国药物应用与检测,2006,4(6):1-4.
  • 7Hayes RP, Curtis B, Ilag L, et al. Expectations about insulin therapy, perceived insulin-delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in in- sulin therapy self efficacy in patients with type 2 diabetes after 36 weeks insulin therapy[J]. Journal of Diabetes, 2013,5 (3) : 358-367.
  • 8Du B, Liu $, Cui C, et al. Association between glucose trans- porter 1 rs841853 polymorphism and type 2 diabetes mellitus risk may be population specific (lrs8418532) [J:. Journal of Diabetes,2013,5(3) :291-299.
  • 9Weir MR, Hollenberg NK, Zappe DH, et al. Antihypertens- ive effects of double the maximum dose of valsartan in Afri- can-American patients with type 2 diabetes mellitus and albu- minutia[J]. Journal of Hypertension, 2010,28 ( 1 ) : 186-193.
  • 10Mogensen E.Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy[J].Scand Clin Lab Invest,1986,46(3):201-206.

引证文献10

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部